Home Back Issues February 2009 Next: an anti-malarial drug

Next: an anti-malarial drug

| Print |  Email
Archives - February 2009
Sunday, February 01, 2009
mosquito.jpg

In the race to cure malaria, the devastating disease that claims 1 million lives each year, every development is critical. The deadliest strain has grown increasingly resistant to chloroquine, the safest and cheapest anti-malarial drug available. The parasite that carries the virus has developed a “siphon” to purge the drug from itself. But instead of developing a new drug, a lengthy and costly process, Portland State University professor David Peyton and his research team at DesignMedix are re-engineering the original. These “reversed chloroquines” block the parasite’s siphon, killing the parasite. Some of these molecules are 10 times more effective than chloroquine alone, decreasing the required dosage significantly. Smaller doses could mean fewer side effects and lower manufacturing costs, Peyton says. The drug is expected to move to human trials in the next two to three years. Peyton sees the eradication of the disease as critical to the health of women and children, and for the health of malaria-stricken countries. “What the world needs now,” Peyton says, “is very good, very safe, very cheap anti-malarial drugs.”

NICOLE STORMBERG



Have an opinion? E-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 

More Articles

Managing family assets: The importance of planning ahead

News
Friday, August 22, 2014
Unknown-1BY CLIFF HOCKLEY |  OB GUEST CONTRIBUTOR

When business intersects with family, a host of  situations can arise. Without a clear vision and careful planning, hard-earned investments can become stressful burdens.


Read more...

Risks & rewards of owning triple net investments

Contributed Blogs
Thursday, July 24, 2014
NNNinvestmentBY CLIFF HOCKLEY | OB GUEST CONTRIBUTOR

With the increasing retirements of Baby Boomers, a massive real estate shift has created a significant increase in demand for NNN properties. The result? Increased demand has triggered higher prices and lower yields.


Read more...

What I'm Reading

September 2014
Wednesday, August 27, 2014

Kim Ierian, President of Concorde Career Colleges, and Deborah Edward, Executive Director of Business for Culture & the Arts, share their recent reads.


Read more...

Is this employee right?

Contributed Blogs
Wednesday, August 13, 2014
081314 thumb employeefeelingsBY TOM COX | OB BLOGGER

When I say, “Your Employee is Always Right,” I do not mean “right about the facts,” but rather “right about how they feel” and “right about how they want to be led.”


Read more...

Back to School

September 2014
Wednesday, August 27, 2014
BY LEE VAN DER VOO

By now we’ve all read the headlines: Starbucks is giving away free degrees. Except it isn’t.


Read more...

Video: The 100 Best Survey

News
Thursday, August 28, 2014

100-best-logo-2015 500pxw-1OB Research Editor Kim Moore shares some pointers about the 100 Best Companies to Work For survey.


Read more...

Powerlist: Colleges and Universities

September 2014
Wednesday, August 27, 2014
BY KIM MOORE

A conversation about higher education with the presidents of the University of Oregon and Clackamas Community College, followed by September's powerlist.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS